Zevra Therapeutics, Inc. (ZVRA) Tops Q4 EPS by 53c

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q4 EPS of $0.60, $0.53 better than the analyst estimate of $0.07. Revenue for the quarter came in at $36.2 million versus the consensus estimate of $31.96 million.

For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.

You May Also Be Interested In

• EQT And KKKR Said Among Firms Considering Bids For Qiagen - Bloomberg
• Buffalo airport blames circuit fault, not shortage, for 3 flight delays
• NAPCO Security Tech (NSSC) Tops Q4 EPS by 11c